Osaic Holdings’s Crescent Biopharma CBIO Stock Holding History

Osaic Holdings’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$468	Hold	26	–	–	﹤0.01%	7663
2026 Q1	$477	Hold	26	–	–	﹤0.01%	7447
2025 Q4	$308	Hold	26	–	–	﹤0.01%	7516
2025 Q3	$374	Buy	+26	New	+$345	﹤0.01%	7598
2023 Q1	–	Sell	-6	Closed	-$2K	–	7529
2022 Q4	$2K	Hold	6	–	–	﹤0.01%	6651
2022 Q3	$0	Hold	6	–	–	﹤0.01%	7344
2022 Q2	$0	Hold	6	–	–	﹤0.01%	7440
2022 Q1	$490K	Hold	6	–	–	﹤0.01%	3241
2021 Q4	$1K	Sell	6 -5	-45%	-$907	﹤0.01%	7181
2021 Q3	$2K	Hold	11	–	–	﹤0.01%	6851
2021 Q2	$3K	Hold	11	–	–	﹤0.01%	6588
2021 Q1	$3K	Hold	11	–	–	﹤0.01%	6364
2020 Q4	$4K	Buy	+11	New	+$3.85K	﹤0.01%	5845

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Osaic Holdings's CBIO Position: Q2 2026 in Review

Osaic Holdings held its Crescent Biopharma (CBIO) position steady in Q2 2026 at 26 shares worth $468. The position accounts for ﹤0.01% of the portfolio, ranked #7663.

Osaic Holdings first reported a position in CBIO in Q4 2020 and has held it in 13 quarters since. The position peaked at $490K in Q1 2022. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

Osaic Holdings held 26 shares of Crescent Biopharma worth $468 as of Q2 2026.
Osaic Holdings left its Crescent Biopharma share count unchanged in Q2 2026.
Crescent Biopharma made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7663 holding.
Osaic Holdings first reported a position in Crescent Biopharma in Q4 2020 and has held it in 13 quarters since.
Osaic Holdings's Crescent Biopharma position peaked at $490K in Q1 2022.
82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.